• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now?

作者信息

Di Pierro Giulia, Mini Enrico, Roviello Giandomenico

机构信息

School of Human Health Sciences, University of Florence, Florence, Italy.

Department of Health Sciences, University of Florence, Florence, Italy.

出版信息

Ann Transl Med. 2019 Sep;7(Suppl 6):S229. doi: 10.21037/atm.2019.07.70.

DOI:10.21037/atm.2019.07.70
PMID:31656808
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6789360/
Abstract
摘要

相似文献

1
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now?卡博替尼治疗晚期非透明细胞肾细胞癌：现在道路更清晰了吗？
Ann Transl Med. 2019 Sep;7(Suppl 6):S229. doi: 10.21037/atm.2019.07.70.
2
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC).卡博替尼在治疗晚期非透明细胞肾细胞癌（NCCRCC）中的临床应用概述。
Crit Rev Oncol Hematol. 2020 May;149:102921. doi: 10.1016/j.critrevonc.2020.102921. Epub 2020 Mar 3.
3
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.卡博替尼对比依维莫司治疗晚期肾细胞癌（METEOR）：一项随机、开放标签、III 期临床试验的最终结果。
Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.
4
Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma.卡博替尼用于转移性透明细胞肾细胞癌的治疗
J Kidney Cancer VHL. 2018 Oct 8;5(4):1-5. doi: 10.15586/jkcvhl.2018.109. eCollection 2018.
5
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.卡博替尼治疗转移性非透明细胞肾细胞癌患者：回顾性分析。
Eur J Cancer. 2018 Nov;104:188-194. doi: 10.1016/j.ejca.2018.08.014. Epub 2018 Oct 28.
6
Cabozantinib: A Review in Advanced Renal Cell Carcinoma.卡博替尼：晚期肾细胞癌的研究进展。
Drugs. 2016 Dec;76(18):1771-1778. doi: 10.1007/s40265-016-0661-5.
7
Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma.综述：卡博替尼治疗晚期肾细胞癌和肝细胞癌
Cancer Manag Res. 2020 May 20;12:3741-3749. doi: 10.2147/CMAR.S202973. eCollection 2020.
8
Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.卡博替尼治疗晚期肾细胞癌：临床试验证据与经验
Ther Adv Urol. 2016 Dec;8(6):338-347. doi: 10.1177/1756287216663073. Epub 2016 Aug 16.
9
Cabozantinib for the treatment of renal cell carcinoma.卡博替尼用于治疗肾细胞癌。
Expert Opin Pharmacother. 2016 Dec;17(18):2499-2504. doi: 10.1080/14656566.2016.1258059. Epub 2016 Nov 22.
10
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.卡博替尼与依维莫司治疗晚期肾细胞癌的疗效对比
N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.

引用本文的文献

1
ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an mA-dependent manner.ALKBH5通过以mA依赖的方式调节AURKB表达来促进肾细胞癌的增殖。
Ann Transl Med. 2020 May;8(10):646. doi: 10.21037/atm-20-3079.

本文引用的文献

1
Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.转移性非透明细胞肾细胞癌患者接受靶向治疗的生存和临床预后因素：一项多机构、回顾性研究，使用韩国转移性肾细胞癌登记处。
Cancer Med. 2019 Jul;8(7):3401-3410. doi: 10.1002/cam4.2222. Epub 2019 May 9.
2
Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes.转移性嫌色细胞肾细胞癌：肉瘤样分化的存在或缺失决定临床过程和治疗结果。
Clin Genitourin Cancer. 2019 Jun;17(3):e678-e688. doi: 10.1016/j.clgc.2019.03.018. Epub 2019 Apr 1.
3
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.卡博替尼治疗晚期非透明细胞肾细胞癌：多中心回顾性队列研究。
Lancet Oncol. 2019 Apr;20(4):581-590. doi: 10.1016/S1470-2045(18)30907-0. Epub 2019 Feb 28.
4
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.卡博替尼治疗转移性非透明细胞肾细胞癌患者：回顾性分析。
Eur J Cancer. 2018 Nov;104:188-194. doi: 10.1016/j.ejca.2018.08.014. Epub 2018 Oct 28.
5
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.癌症基因组图谱：肾细胞癌的全面分子特征
Cell Rep. 2018 Jun 19;23(12):3698. doi: 10.1016/j.celrep.2018.06.032.
6
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.卡博替尼对比舒尼替尼作为低危或中危转移性肾细胞癌患者的初始靶向治疗：联盟A031203 CABOSUN试验
J Clin Oncol. 2017 Feb 20;35(6):591-597. doi: 10.1200/JCO.2016.70.7398. Epub 2016 Nov 14.
7
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.卡博替尼对比依维莫司治疗晚期肾细胞癌（METEOR）：一项随机、开放标签、III 期临床试验的最终结果。
Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.
8
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.《2016 年世界卫生组织泌尿系统及男性生殖器官肿瘤分类—第 A 部分：肾脏、阴茎和睾丸肿瘤》。
Eur Urol. 2016 Jul;70(1):93-105. doi: 10.1016/j.eururo.2016.02.029. Epub 2016 Feb 28.
9
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.依维莫司对比舒尼替尼治疗转移性非透明细胞肾细胞癌患者（ASPEN）：一项多中心、开放标签、随机2期试验
Lancet Oncol. 2016 Mar;17(3):378-388. doi: 10.1016/S1470-2045(15)00515-X. Epub 2016 Jan 13.
10
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.依维莫司对比舒尼替尼用于转移性非透明细胞肾细胞癌的前瞻性评估（ESPN）：一项随机多中心2期试验
Eur Urol. 2016 May;69(5):866-74. doi: 10.1016/j.eururo.2015.10.049. Epub 2015 Nov 26.